NDA 206089 · Tolmar
Jatenzo
Testosterone Undecanoate · Oral
Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Mar 27, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
82
23 Phase 3, 9 recruiting
FAERS reports
563
270 serious, 22 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 13, 2026.
JATENZO (testosterone undecanoate) is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of JATENZO in men with “age-related hypogonadism” have not been established. Safety and efficacy of JATENZO in males less than 18 years old have not been established [ see Use in Specific Populations ( 8.4 ) ]. JATENZO (testosterone undecanoate) is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone ( 1 ). Limitations of use: Safety and efficacy of JATENZO in men with “age-related hypogonadism” have not been established ( 1 ) Safety and efficacy of JATENZO in males less than 18 years old have not been established ( 1 , 8.4 ).
Mechanism: Endogenous androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis and scrotum; the development of male hair distribution, such as facial, pubic, chest and axillary hair; laryngeal enlargement, vocal cord thickening, alterations in body musculature and fat distribution. Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone, has two...
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- JATENZO · TESTOSTERONE UNDECANOATE 237MG · CAPSULE, ORAL · Prescription
- JATENZO · TESTOSTERONE UNDECANOATE 158MG · CAPSULE, ORAL · Prescription
- JATENZO · TESTOSTERONE UNDECANOATE 198MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Testosterone Undecanoate" as an intervention, any sponsor and status, largest first.
- A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With HypogonadismPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT04456296 · 673 participants · Start Jun 30, 2020 · Primary completion Jul 12, 2023
Drug: Aveed Injectable Product; Fortesta and 1 more · For: Hypogonadism; Hypogonadism, Male; Hypogonadotropic Hypogonadism
Sites: Birmingham, Alabama; Tucson, Arizona; North Little Rock, Arkansas · 35 sites in all
- Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal MenPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT00467870 · 531 participants · Start Mar 2006 · Primary completion Jul 2009
Drug: Testosterone Undecanoate 750 mg; Testosterone Undecanoate 1000 mg · For: Hypogonadism; Primary Hypogonadism; Secondary Hypogonadism
Sites: Lexington, Massachusetts
- Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00403793 · 350 participants · Start Oct 2003 · Primary completion Dec 2006
Drug: etonogestrel with testosterone undecanoate; Placebo · For: Contraception
- Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal MenPivotal-lookingCompleted
Clarus Therapeutics, Inc.Industry
NCT01403116 · 325 participants · Start Jul 2011 · Primary completion Sep 2013
Drug: Oral testosterone undecanoate; topical testosterone gel · For: Male Hypogonadism
Sites: Birmingham, Alabama; Calera, Alabama; Huntsville, Alabama · 30 sites in all
- Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00434824 · 322 participants · Start Nov 2001 · Primary completion Jul 2004
Drug: Oral testosterone undecanoate (Andriol); Placebo · For: Hypogonadism; Androgens
- Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or HypogonadismPivotal-lookingCompleted
Lipocine Inc.Industry
NCT02081300 · 315 participants · Start Feb 2014 · Primary completion May 2015
Drug: Oral testosterone undecanoate, LPCN 1021; Topical testosterone gel 1.62 % · For: Male Hypogonadism
- Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal MenPivotal-lookingCompleted
Marius PharmaceuticalsIndustry
NCT03198728 · 314 participants · Start Jul 5, 2017 · Primary completion May 1, 2020
Drug: SOV2012-F1; AndroGel · For: Hypogonadism, Male
Sites: Birmingham, Alabama; Mobile, Alabama; Tucson, Arizona · 36 sites in all
- Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI TrialPivotal-lookingNot yet recruiting
VA Office of Research and DevelopmentFederal agency
NCT07742553 · 300 participants (planned) · Start Oct 1, 2027 · Primary completion Sep 30, 2031
Drug: testosterone cypionate; finasteride and 2 more · For: Spinal Cord Injury; Spinal Cord Injuries; Injuries, Spinal Cord and 11 more
Sites: Aurora, Colorado; Gainesville, Florida; Tampa, Florida · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use60
- drug ineffective33
- fatigue28
- blood testosterone decreased25
- headache25
- therapy interrupted25
- blood testosterone abnormal22
- intentional product use issue22
- product availability issue19
- polycythaemia16
- blood pressure increased15
- asthenia14
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2009 | 3 |
| 2010 | 6 |
| 2011 | 2 |
| 2012 | 9 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 12 |
| 2016 | 7 |
| 2017 | 5 |
| 2018 | 22 |
| 2019 | 8 |
| 2020 | 19 |
| 2021 | 46 |
| 2022 | 29 |
| 2023 | 107 |
| 2024 | 106 |
| 2025 | 100 |
| 2026 | 69 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Jatenzo (Testosterone Undecanoate)
2024 spending
$7.9M
Beneficiaries
1,758
7,521 claims
Per beneficiary
$4,514
$13.20 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $752,675 |
| 2022 | $3,293,190 |
| 2023 | $4,591,544 |
| 2024 | $7,934,922 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism.
Gregorič N, ikonja J, Janež A, et al. · Diabetes Obes Metab 2025 · Randomized Controlled Trial
- Beneficial effects of exercise, testosterone, vitamin D, calcium and protein in older men-A randomized clinical trial.
Midttun M, Overgaard K, Zerahn B, et al. · J Cachexia Sarcopenia Muscle 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Long-term Outcomes of Testosterone Treatment in Men: A T4DM Postrandomization Observational Follow-up Study.
Handelsman DJ, Grossmann M, Yeap BB, et al. · J Clin Endocrinol Metab 2023 · Randomized Controlled Trial
- A Randomized Controlled Trial Comparing Testosterone Enanthate and Testosterone Undecanoate as a Gender Affirming Hormonal Therapy in Trans Males.
Sinju S, Sridhar S, Sreenivasan P, et al. · Clin Endocrinol (Oxf) 2025 · Randomized Controlled Trial, Comparative Study
- Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism.
Miner M, Wang C, Kaminetsky J, et al. · Andrology 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial.
Wittert G, Bracken K, Robledo KP, et al. · Lancet Diabetes Endocrinol 2021 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Tolmar
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.